EBS
NYSE · Biotechnology
Emergent Biosolutions Inc
$7.22
-0.04 (-0.55%)
Open$7.28
Previous Close$7.26
Day High$7.32
Day Low$7.05
52W High$14.06
52W Low$5.06
Volume—
Avg Volume921.5K
Market Cap276.51M
P/E Ratio—
EPS$-0.24
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+275.1% upside
Current
$7.22
$7.22
Target
$27.08
$27.08
$18.81
$27.08 avg
$37.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 501.79M | 575.51M | 356.03M |
| Net Income | 35.53M | 36.67M | -80,261,545 |
| Profit Margin | 7.1% | 6.7% | -22.5% |
| EBITDA | 103.34M | 112.60M | -95,339,299 |
| Free Cash Flow | — | — | -67,766,487 |
| Rev Growth | -12.8% | -12.8% | +7.9% |
| Debt/Equity | 1.09 | 1.09 | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |